 Sorrento Therapeutics Inc NASDAQ: SRNE has announced preclinical results for its mRNA-based COVID-19 vaccine against SARS-CoV-2. STI-mRNA includes a proprietary designer Spike-encoding mRNAs to elicit cellular and humoral immunity against the early virus strain and emerging variants of concern. 